The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years because of Washington's demand for sensitive biological samples.
The decision came to light after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson later explained that the US was seeking genetic material for scientific study and commercial gain while was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued talks to find a deal acceptable to both sides so the country's vital HIV programme can continue.
Wider Context
This development comes after a comparable situation in Kenya, where a high court blocked a related deal with the US following legal challenges were filed about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," his statement read.
"Effectively, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our people if a new health crisis emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems previously established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a country provides its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration might be designed in a manner that honours the independence and dignity of both nations."
Health Experts Response
Medical experts said it recognised the official position, but suggested that negotiations should continue considering a large portion of the country's HIV programmes were funded by external financing.
"In cases where technical issues exist, including those relating to information security or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
The situation emphasises the continuing debate between accepting crucial international aid and protecting a country's data in an increasingly data-driven world.